Adani Energy Solutions Posts Rs 1,190 Cr Loss in Q1
By Rediff Money Desk, New Delhi Jul 25, 2024 16:20
Adani Energy Solutions reported a net loss of Rs 1,190.66 crore in Q1 FY25, driven by increased expenses. The company's total income rose to Rs 5,489.97 crore.
New Delhi, Jul 25 (PTI) Adani Energy Solutions Ltd on Thursday reported a net loss of Rs 1,190.66 crore during the June 2024 quarter, mainly on account of increased expenses.
It had clocked a net profit of Rs 181.98 crore during the April-June period of the preceding 2023-24 fiscal, the company said in a regulatory filing.
The company's total income, however, rose to Rs 5,489.97 crore from Rs 3,772.25 crore in the year-ago period.
During the period under review, expenses surged to Rs 4,443 crore from Rs 3,124.69 crore a year ago.
Adani Energy Solutions Ltd is the largest private sector power transmission company in India.
It had clocked a net profit of Rs 181.98 crore during the April-June period of the preceding 2023-24 fiscal, the company said in a regulatory filing.
The company's total income, however, rose to Rs 5,489.97 crore from Rs 3,772.25 crore in the year-ago period.
During the period under review, expenses surged to Rs 4,443 crore from Rs 3,124.69 crore a year ago.
Adani Energy Solutions Ltd is the largest private sector power transmission company in India.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.84 (+ 3.70)
- 32594408
- Vodafone Idea L
- 9.26 (+ 1.54)
- 25206675
- Filatex Fashions
- 1.01 (+ 4.12)
- 22851789
- Rajnish Wellness
- 3.31 (+ 9.97)
- 22491364
- Spicejet Ltd.
- 64.79 ( -2.53)
- 10876904
MORE NEWS
South Indian Bank Q2 Profit Up 18% to Rs 325 Cr...
South Indian Bank reported an 18% increase in Q2 profit to Rs 325 crore, driven by...
Akums Drugs Inks Licensing Pact with Canadian...
Akums Drugs and Pharmaceuticals has signed a licensing agreement with Triple Hair Inc....
Wockhardt Seeks Approval for Diabetes Drug...
Wockhardt has filed for marketing approval of its fast-acting insulin analog, Aspart...